Abbott Laboratories (ABT) News $ABT
China Adalimumab Market Investigation Report with 2018 Forecasts Now Available at ChinaMarketResearchReports.com
PRWeb - Fri Mar 21, 9:31PM CDT
Adalimumab is a TNF (tumor necrosis factor) inhibiting antiinflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF Pharma by Abbott. In 2000 Abbott Laboratories took over Knoll with USD 6.9 billion. At the end of 2002 adalimumab was approved to the market by FDA.
After Yesterday's Decline of 1.44%, Abbott Laboratories Offers Investors Better Value
Comtex SmarTrend(R) - Thu Mar 20, 3:54PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $38.78 to a high of $39.64. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $39.04 on volume of 10.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Sucampo's NDA Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:05PM CDT
Sucampo Pharma recently announced that its New Drug Application (NDA) for the liquid formulation of Amitiza will not be filed in the second half of 2014.
Drug Device Combination Products Market Report 2013 - 2019: Forecasts & Trends for the $US100 Billion Market
M2 - Tue Mar 18, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wmt3kk/drug_device) has announced the addition of the "Drug Device Combination Products Market Report 2013 - 2019: Forecasts & Trends for the $US100 Billion Market" report to their offering. The global drug device combination products market was valued at USD 66 billion in 2012 and is expected to grow at a CAGR of 7.9% from 2013 to 2019, to reach an estimated value of USD 115 billion in 2019. This report studies the global market for drug device combination products from the perspective of product types. The market is thus segmented into drug eluting stents, infusion pumps, bone graft implants, photodynamic therapy, wound care combination devices, inhalers, transdermal patches and others including intraocular implants and drug eluting beads. The market for all these product segments is also analyzed for four major geographic regions namely North America, Europe, Asia and the rest of the world (RoW) regions. The markets for all these segments is analyzed and estimated in USD billion. Each of the segments have been analyzed on the basis of its current and future market size for the period 2011 to 2019, in terms of revenue generation in USD billion, considering 2011 and 2012 as the base years. The compounded annual growth rate (%CAGR) for each market segment has been provided for the forecast period 2013 to 2019 along with the estimations of market size. A competitive landscape, mapping all the market players and their respective market shares for 2012 are provided in this report for drug eluting stents and infusion pumps. A chapter on recommendations for existing and new entrants is also provided in this report. Drug Device Combination Products Market: - Drug Eluting Stents - Infusion Pumps - Photosensitizers - Orthopedic Combination Products - Wound Care Combination Products - Inhalers - Transdermal Patches - Intraocular Implants and Drug Eluting Beads Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Drug Device Combination Products, by Type, Size and Forecast, 2011-2019 (USD Billion) Chapter 5 Global Drug Device Combination Products, by Geography, 2011 - 2019 (USD Million) Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles - Abbott Laboratories - Alcon, Inc. - Allergan, Inc. - Arrow International, Inc. - Bausch & Lomb, Inc. - Boston Scientific Corporation - C.R. Bard, Inc. - CareFusion Corporation - Covidien PLC - Ethicon, Inc. - Medline Industries, Inc. - Medtronic, Inc. - Mylan, Inc. - Pinnacle Biologics, Inc. - Stryker Corporation - Terumo Corporation - W. L. Gore & Associates, Inc. For more information visit http://www.researchandmarkets.com/research/wm...rug_device
Next Resistance Level for Abbott Laboratories (ABT) is $39.88
Comtex SmarTrend(R) - Tue Mar 18, 10:44AM CDT
Abbott Laboratories (NYSE:ABT) has opened bullishly above the pivot of $39.37 today and has reached the first level of resistance at $39.69. Investors may be interested in a cross of the next upside pivot targets of $39.88 and $40.39.
Global Imaging Biomarkers Market 2014-2018 with Abbott, Agilent, Affymetrix, Siemens, Bio-Rad & F. Hoffmann La Roche Dominating
M2 - Tue Mar 18, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brn9sx/global_imaging) has announced the addition of the "Global Imaging Biomarkers Market 2014-2018 with Abbott, Agilent, Affymetrix, Siemens, Bio-Rad & F. Hoffmann La Roche Dominating" report to their offering. The use of imaging biomarkers in the field of drug discovery has increased considerably over the past few years. The increase in the demand for imaging biomarkers is primarily because of their ability to be used in target discovery and validation, identification of disease mechanisms, toxicity profiling, and proof-of-concept studies. The Global Imaging Biomarkers market has been witnessing an increase in the number of strategic alliances being formed among organizations. Mergers and acquisitions help organizations grow rapidly, expand their business processes, and gain more market share. The introduction of innovative technologies by small and mid-sized companies is prompting major pharmaceutical and biotechnology companies to form strategic alliances with these smaller companies to identify various imaging biomarkers. The increase in strategic alliances is resulting in an increase in the application base for imaging biomarkers in drug discovery and diagnosis domains. For instance, in 2012, Genomic Health Inc. and OncoMed Pharmaceuticals announced a strategic alliance for Biomarker Research and Discovery using the Next-generation Sequencing process. Further, the report states that one of the main challenges hindering the growth of this market is the presence of poor regulatory and reimbursements systems. The current regulatory and reimbursement systems present in various countries are not well-suited for imaging biomarker-based diagnostics. The development of novel and useful imaging biomarkers is also an expensive and time-consuming process. The key vendors dominating this market space are: - Abbott Laboratories - Agilent Technologies Inc. - Affymetrix Inc. - Bio-Rad Laboratories Inc. - F. Hoffmann La Roche Ltd. - Gen-Probe Inc. - Siemens Healthcare. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Geographical Segmentation 08. Buying Criteria 09. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Trends and their Impact 15. Vendor Landscape 16. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/br...al_imaging
Critical Alerts For Yelp, SolarCity, MannKind, CVS, and Abbott Labs Released By InvestorsObserver
PR Newswire - Tue Mar 18, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for YELP, SCTY, MNKD, CVS, and ABT.
Eternity Healthcare to Initiate a Large Scale Clinical Trial of Its Needle-Free Injection System in Patients Undergoing Fertility Treatments Using the Drug Gonadotropins
Business Wire - Mon Mar 17, 7:25AM CDT
Eternity Healthcare Inc. (OTCBB: ETAH), a medical device and diagnostic company, announced today that they have signed an agreement with a major fertility clinic, Pacific Center for Reproductive Medicine. Eternity Healthcare and Pacific Center for Reproductive Medicine (PCRM) will partner for a large clinical trial that will use the Comfort-in(TM) Needle-Free Injection System in PCRM patients undergoing fertility treatments using the drug Gonadotropins.
Microfluidics Market Report 2013-2018: Materials, Pharmaceuticals, Drug Delivery Devices & IVD
M2 - Fri Mar 14, 9:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zswzc/microfluidics Normal 0 false false false EN-IE X-NONE X-NONE ) has announced the addition of the "Microfluidics Market Report 2013-2018: Materials, Pharmaceuticals, Drug Delivery Devices & IVD" report to their offering. The microfluidics market is segmented based on materials, products, and applications. This report studies market trends for the above mentioned segments in three industries, namely, pharmaceutical, in-vitro diagnostics, and drug delivery devices. The market is expected to grow at a strong CAGR during the study period. This is due to factors such as the rising demand for POC devices, quick return on investments provided by microfluidics devices which helps in cost reductions, and miniaturization of microfluidic chips. However, factors such as difficulty in incorporation of emerging microfluidic technologies into existing workflows and complex and time consuming regulatory standards are hampering the growth of this market. Microfluidics is defined as the science of designing, fabricating, and formulating products and processes that deal with low volumes of fluids in the range of nanoliters or picoliters. The technology evolved from MEMS (Micro Electro Mechanical Systems) devices and can replicate all the functions of its counterparts in various healthcare applications such as, drug delivery, Point-of-Care (POC), and clinical diagnostics. This study covers the materials, industries, and applications revenue markets for the global market. The global revenue generated from various microfluidics products used in three industries, namely, pharmaceutical, in-vitro diagnostics, and drug delivery devices is considered to estimate the market size. Material - Polymer-based Microfluidics - Glass-based Microfluidics - Silicon-based Microfluidics - Other Material-based Microfluidics Industry Pharmaceuticals - -- Microfluidic Chips for Laboratory Analytics - --- Toxicity Screening - --- Proteomics Analysis - --- Gene Sequencing - --- Capillary Electrophoresis - -- Accurate Dispensing Devices - -- Microreactors for Drug Synthesis - -- In-Vitro Diagnostics - --- Clinical Diagnostics - --- Point--- of--- Care Testing - --- Environmental Testing - --- Industrial Testing - --- Agro Food Testing - -- Drug Delivery Devices - --- Inhaler Nozzles - --- Micro Needles - --- Micro Pumps Application - Drug Delivery - Industrial and Environmental - Analytical Devices - Pharmaceutical and Life Sciences Research - Point-of-Care Diagnostics - Clinical and Veterinary Diagnostics Companies Mentioned - Abbott Laboratories, Inc. - Agilent Technologies - Bartels Mikrotechnik Gmbh - Becton, Dickinson And Company 1 Becton Drive - Bio-Rad Laboratories, Inc. - Biofluidix Gmbh - Cepheid, Inc. - Danaher Corporation - Fluidigm Corporation - Johnson & Johnson - Life Technologies Corporation - Microfluidic Chipshop Gmbh - Perkinelmer, Inc. - Raindance Technologies - Roche Diagnostics Limited - Scienion Ag - Siemens Healthcare For more information visit http://www.researchandmarkets.com/research/7z...rofluidics Normal 0 false false false EN-IE X-NONE X-NONE
Concise Analysis of the International Enteral Feeding Devices Market - Forecasts to 2016
M2 - Fri Mar 14, 5:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7v8b8b/global_enteral) has announced the addition of the "Concise Analysis of the International Enteral Feeding Devices Market - Forecasts to 2016" report to their offering. Currently, the increasing use of low-profile feeding tubes is replacing standard G-tubes used for providing enteral nutrition. Low-profile tubes provide feeds to patients directly through the abdomen. They terminate at skin level, are more easily hidden, and incur fewer accidental removals than G-tubes which have longer length of exposed tubing. Moreover, low-profile tubes with balloon can be replaced at home without the need for anesthetic or hospital admission. One of the main drivers in this market is the increase in rate of premature births. Preterm infants are not able to control and coordinate sucking, swallowing or breathing thus, generating the need for enteral feeding devices to provide them with sufficient nutritional requirements for growth and development. Further, the report states that one of the major challenges in the market is the complications with enteral feeding tubes such as tube blockage, aspiration pneumonia, and contamination of feed. The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are Nestl? HealthCare Nutrition Inc., Amsino International Inc., Applied Medical Technology Inc., Caesarea Medical Electronics, CORPAK MedSystems Inc., and Vygon Corp. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Vendor Landscape 9. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Key Vendor Analysis 16. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Amsino International Inc. - Applied Medical Technology Inc. - Caesarea Medical Electronics - CORPAK MedSystems Inc. - Covidienplc - Fresenius Kabi AG - Moog Inc. - Nestl? HealthCare Nutrition Inc. - Vygon Corp. For more information visit http://www.researchandmarkets.com/research/7v...al_enteral
SmarTrend Watching for Potential Rebound in Shares of Abbott Laboratories After 1.08% Loss
Comtex SmarTrend(R) - Thu Mar 13, 5:24PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $39.10 to a high of $39.82. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $39.41 on volume of 7.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Pre-Market Health Care Stocks Analysis: Medtronic, Abbott Laboratories, Hologic, and ArthroCare
PR Newswire - Thu Mar 13, 7:00AM CDT
On Wednesday, March 12, 2014, the NASDAQ Composite ended at 4,323.33, up 0.37%, the Dow Jones Industrial Average fell 0.07% to 16,340.08, and the S&P 500 closed at 1,868.20, up 0.03%. The gains were narrow based as four out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 687.90, down 0.01%, while the same has gained 3.36% in the last one month. Investor-Edge.com has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Hologic Inc. (NASDAQ: HOLX), and ArthroCare Corporation (NASDAQ: ARTC). Free research on these four companies can be accessed at:
2014 Hormone Replacement Therapy Global Strategic Business Report - IMS Consensus Guidelines Paving Way for More Clarity of HRT
M2 - Thu Mar 13, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/657h9p/hormone) has announced the addition of the "Hormone Replacement Therapy (HRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Hormone Replacement Therapy (HRT) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS & ISSUES 4. COMPETITIVE LANDSCAPE 5. THERAPY PROFILE - A REVIEW OF SELECT RECENT STUDIES CONDUCTED - Researchers at Yale University Discover Discontinuation HRT May Lead to Premature Deaths - Bioidenticals versus Synthetic Hormone Replacement Therapy Agents - Studies at University of Sydney Researchers Reveal the Safety of Short-Term Unopposed Estrogens - US Researchers Reveal HRT Risks May be Dependent on Weight and Other Factors - Studies Prove HRT to Lower Risk of Pancreatic Cancer - University of Texas Reveal HRT Linked to Risks of Kidney Stones - Researchers at the Sundsvall Hospital Demonstrate Increased Incidence of Cataract Development in Women Undergoing HRT - Researchers at University of Southern California Demonstrate Estrogen Replacement Therapies Lower Stress Levels in Older Women - Studies at Uppsala University Hospital Demonstrate HRT is Associated with Improved Muscle Functioning in Postmenopausal women - Finnish Study Reveals HRT Usage Assist in the Treatment of Hot Flashes in Post Menopausal Women - Researchers at Johns Hopkins University Demonstrate Women Undergoing Hormone Therapy Less Prone to Alzheimer's Disease - French Study Reveals Hormone Replacement Pills May Affect Gall Bladder - Danish Studies Proves HRT Lowers Risk of Heart Attack and Heart Failure 6. PRODUCT OVERVIEW 7. PRODUCT INTRODUCTIONS/APPROVALS - Pfizer Receives FDA Approval for DUAVEE for Treatment of Vasomotor Symptoms - Noven Pharmaceuticals Launches Brisdelle Capsules - Lawley Pharmaceuticals Launches Profeme progesterone Bioidentical Hormone Replacement Cream - Bayer Receives FDA Approval for Low-Dose ANGELIQ? Tablets - Noven Pharmaceuticals Receives USFDA Approval for Minivelle - Mylan Pharmaceuticals Introduces Letrozole Tablets - Novo Nordisk Unveils Vagifem? 10?g - Amgen Obtains FDA Approval for Prolia in Treating Postmenopausal Women at Greater Risk of Osteoporosis 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 40 companies including many key and niche players such as: - Abbott Laboratories - AbbVie - Actavis - Bayer Pharma - Bayer Pharma's Hormone Replacement Therapy Product Pipeline - Hisamitsu Pharmaceutical - Noven Pharmaceuticals - Merck Sharp & Dohme - Novartis - Novo Nordisk - Orion - Pfizer - Rottapharm Madaus - Teva Pharmaceutical Industries - TherapeuticsMD - Upsher-Smith Laboratories For more information visit http://www.researchandmarkets.com/research/657h9p/hormone About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Chinese Adalimumab Market Report - Forecasts to 2018
M2 - Wed Mar 12, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/936hbj/investigation) has announced the addition of the "Chinese Adalimumab Market Report - Forecasts to 2018" report to their offering. Adalimumab is a TNF (tumor necrosis factor) inhibiting anti-inflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF Pharma by Abbott. In 2000 Abbott Laboratories took over Knoll with USD 6.9 billion. At the end of 2002 adalimumab was approved to the market by FDA. Duo to large market size, challenging R&D and high profit of the monoclonal antibody drug market, the collaboration between Huahai Pharmaceutical and Oncobiologics is praised by the industry as the ""Second Transformation"" supported by the international biopharmaceutical giant's strong R&D strength. The approval for adalimumab to launch phase I clinical trial means a significant progress of the collaboration. However, follow-up R&D of the monoclonal antibody product requires a large amount of time before the product appears on the market. It is estimated that Abbott will continue to occupy the global market of adalimumab in the next few years. However, the situation will change gradually after 2017. Key Topics Covered: 1 Relevant Concepts of Adalimumab 2 Market Overview of Adalimumab in China, 2010-2013 3 Investigation on Sales Value of Adalimumab in China, 2010-2013 4 Investigation on Market Share of Major Adalimumab Manufacturers in China, 2010-2013 5 Investigation on Market Size of Adalimumab by Dosage Form in China, 2010-2013 6 Reference Price of Adalimumab in China Adalimumab Hospital Market, 2013 7 Analysis on Major Adalimumab Manufacturers in China, 2010-2013 8 Prospect of China Adalimumab Market, 2014-2018 Companies Mentioned - AbbVie - BASF Bioresearch Corporation - BASF Pharma - Huahai Pharmaceutical For more information visit http://www.researchandmarkets.com/research/93...estigation
Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Wed Mar 12, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mdgmns/rapid_medical) has announced the addition of the "Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid medical diagnostic kits market is experiencing impressive growth globally because of the continuous increase in demand for preventive management of infectious diseases. Since its introduction, rapid medical diagnostic kits are becoming a vital part of the medical diagnostics industry and the scope of this market has been perpetually increasing in terms of detectable diseases and adoption by end users. This report studies the global market for rapid diagnostic kits through three major perspectives namely, application areas, technologies and geography. The application segment of this market has been further segmented into three sub-divisions namely clinical testing, home-use and veterinary diagnostics. In addition, the technology segment of rapid medical diagnostic kits market has been categorized into lateral flow, flow-through, agglutination assays and solid phase. Each of the above segments are analyzed on the basis of their market size (in terms of USD million) for the period 2011 to 2019. This also includes the forecast of the market segments in terms of CAGR (%) for the period 2013 - 2019, considering 2012 as the base year. Geographically, the rapid medical diagnostic kits market is categorized into four regions namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market revenues (for the period 2011 - 2019) and forecast (for the period 2013 - 2019) for each of these regions have been included in this report. The market overview section of the report demonstrates the qualitative analysis of the market dynamics of the global rapid medical diagnostic kits market and thus includes information about the drivers, restraints, opportunities, Porter's five forces model and market attractiveness analysis of this industry. Key Topics Covered: Introduction Executive Summary Rapid Medical Diagnostic Kits Market Overview Global Rapid Medical Diagnostic Kits Market, by Applications, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Technology, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Geography, 2011 - 2019, (USD Million) Recommendations Competitive Landscape Companies Mentioned - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - MegaCor Diagnostik GmbH - F. Hoffmann-La Roche Ltd. - Trinity Biotech plc - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/md...id_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The US Nutraceuticals Market is Estimated to Reach US$ 75.3 Billion in 2017 says recent Report
M2 - Tue Mar 11, 11:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78hlpr/us_nutraceuticals) has announced the addition of the "US Nutraceuticals Market Forecast to 2017" report to their offering. In the latest research study, US Nutraceuticals Market Forecast to 2017, RNCOS analysts identified and deciphered the market dynamics in important segments to clearly highlight the areas offering promising possibilities for companies to boost their growth. The market, which is estimated to reach US$ 75.3 Billion in 2017, is slated to grow at a CAGR of nearly 6% during 2013-2017. The tremendous growth of the market is driven by factors such as rising consumption of dietary supplements and propelling functional food & beverages market. In the present report, the US nutraceutical market has been broken down into three distinct segments: dietary supplements, functional food and functional beverages, with their current and future outlook to 2017. For market performance analysis, the dietary supplements dominate the market by acquiring a share of around 37%, followed by functional food and functional beverages. In addition, the report also covers the nutraceutical ingredient market along with its sub segments which helped the analysts to clearly identify and highlight the segments that offer the maximum opportunity for growth in the country. The study further delves into the detailed description of the major players in industry, covering description of their business, financials, and their recent developments. This will help the reader to gain a deeper insight into each key market player. Moreover, market drivers and trends have been discussed along with consumer behavior analysis and regulatory framework analysis to provide an understanding of the market dynamics. Companies Mentioned: - Abbott Laboratories - GNC Holdings, Inc. - Mead Johnson Nutrition Company - NBTY Inc. - Nestle USA, Inc. - Perrigo Company - The Hain Celestial Group, Inc. For more information visit http://www.researchandmarkets.com/research/78...aceuticals About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Abbott Laboratories (ABT) Breaks Through Resistance at $40.00
Comtex SmarTrend(R) - Tue Mar 11, 9:31AM CDT
Abbott Laboratories (NYSE:ABT) has opened bullishly above the pivot of $39.71 today and has reached the first level of resistance at $40.00. Should the shares continue to rise, the resistance pivots of $40.19 and $40.67 will be of interest.
Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017
M2 - Tue Mar 11, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nc4zfn/in_vitro) has announced the addition of the "Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017" report to their offering. The in vitro diagnostic market studied in this report has been segmented by technology, product type, application, end user, and geography. The technology market is further segmented into clinical chemistry, immunochemistry, molecular diagnostics, hematology, coagulation, microbiology, and others, of which immunochemistry accounted for the largest share with 25.8% in 2010. By product type, the IVD market has segments like instruments, reagents, data management software/hardware, and services. Based on applications, the in vitro diagnostic market is segmented as diabetes, infectious diseases, oncology, cardiology, nephrology, auto-immune diseases, AIDS, drug testing, and others. Laboratory testing, hospital testing, academic (AMCs and university) testing, point-of-care testing, patient self-testing, and others comprise the end-user segment of the IVD market. The global in vitro diagnostic market was valued at $49.2 billion in 2012 and is expected to reach $69.1 billion by 2017, at a CAGR of 7% from 2012 to 2017. The IVD market is primarily driven by rising incidences of chronic and infectious diseases in emerging economies, a rapidly aging population, the rise in point-of-care testing, and the rising importance of personalized medicine. However, factors such as stringent regulatory frameworks and a shortage of budget and labor are restraining the growth of the market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global In Vitro Diagnostic Market, By Technique 5 Global In Vitro Diagnostic Market, By Product Type 6 Global In Vitro Diagnostic Market, By Application 7 Global In Vitro Diagnostic Market, By End-User 8 Geographic Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc - Alere, Inc - Arkray, Inc - Bayer AG - Becton, Dickinson And Company - Bio-Rad Laboratories, Inc - Biomerieux - Danaher Corporation - Diagnostica Stago Sas - Diasorin SPA - Hologic, Inc - Horiba, Ltd - Johnson & Johnson - Novartis International Ag - Qiagen NV - Roche Diagnostics Limited - Siemens Healthcare - Sysmex Corporation - Thermo Fisher Scientific, Inc For more information visit http://www.researchandmarkets.com/research/nc4zfn/in_vitro
2014 Wireless Health and Fitness Devices Global Strategic Business Report - Increasing Obesity Levels Underpins Market Growth
M2 - Tue Mar 11, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/swfb49/wireless_health) has announced the addition of the "Wireless Health and Fitness Devices - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Wireless Health and Fitness Devices in Thousand Units by the following Product Segments: Wireless Sports & Fitness Devices, Wireless Remote Health Monitoring Devices, and Wireless Professional Healthcare Devices. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2011 through 2020. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK - Wireless Health and Fitness Monitoring Devices Market to Surge - Market Drivers - Wearable Sports and Fitness Devices - Wearable Health Devices - Market Challenges - Wearable Sports and Fitness Devices - Wearable Health Devices 2. TRENDS & ISSUES 3. WIRELESS HEALTH AND FITNESS SOLUTIONS - AN OVERVIEW - Wireless Health and Fitness: An Introduction - Product Segments - Wireless Sports & Fitness Devices - Wireless Remote Health Monitoring Devices - Wireless Professional Healthcare Devices - What is Wireless Health? - Evolution of Wireless Health - Wireless Health Development with M2M Solutions - Value Chain in Mobile Healthcare - Available Wireless Medical Solutions - Wireless Standards for Medical Applications - ZigBee - Bluetooth - Broadband - Wireless Sensor Networks - Applications of Wireless Sensors for Enhanced Healthcare - Chronic Disease Monitoring - Personal Wellness Monitoring - Personal Fitness Monitoring - Benefits of Using Wireless Healthcare Solutions - More Affordable Healthcare - Preventive Healthcare - Better Accessibility to Healthcare - Chronic Disease Management - Key Benefits of Wireless Remote Patient Monitoring Devices - Primary Factors Limiting Success of Remote Patient Monitoring Devices 4. PRODUCT/SERVICE INNOVATIONS/ INTRODUCTIONS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. JAPAN 3. EUROPE 4. ASIA-PACIFIC 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 136 companies including many key and niche players such as: - Abbott Laboratories - Adidas - Alive Technologies - Beuer - BodyMedia - Bosch Healthcare - Entra Health Systems - FitLinxx - Fitbit - Garmin - Ideal Life - Intelesens - Isansys Lifecare - Jawbone - Lumo BodyTech - Medtronic - Nike - Nonin Medical, - Nuvon - Oregon Scientific - Philips Healthcare - Polar Electro - Sensei - Sotera Wireless - Suunto - Toumaz UK - Wahoo Fitness - Withings - Zephyr Technology For more information visit http://www.researchandmarkets.com/research/sw...ess_health About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Investigation Report on China's Telmisartan Market Report 2014 - Forecasts to 2018
M2 - Mon Mar 10, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jqmhqf/investigation) has announced the addition of the "Investigation Report on China Telmisartan Market, 2009-2018" report to their offering. According to statistics from WHO, one-third of the world's adults have high blood pressure. Death toll of this disease equals to half of the total number caused by stroke and heart attack. Angiotensin II receptor antagonist (ABR) is an important product among various antihypertensive drugs. Telmisartan was firstly developed by Boehringer Ingelheim and approved to the U.S. market for the first time in 1999 with the trade name ""Micardis"". It is a once-daily oral medication for the treatment of essential hypertension. In the same year, telmisartan was jointly sold as ""Micardis"" by Boehringer Ingelheim and ""Pritor"" by Glaxo Wellcome in Germany. It was approved to market in December 1999 in Philippines. In 2000, it was approved to market in Australia, Belgium and Britain. Glaxo Wellcome owns the marketing right worldwide except in Japan and the U.S. The company is also developing compound preparation of telmisartan and other hypertension drugs. Abbott Laboratories holds the sales license of this product in the United States. At the end of 2000, Boehringer Ingelheim introduced raw material and preparation of telmisartan into Chinese market. Several telmisartan generic drugs have also been approved to Chinese market in succession since 2004. Statistics shows that incidence of hypertension among Chinese people aged 15 and above is 24%. There are more than 260 million hypertension patients in the country, with at least one hypertension patient among 5 adults. The prevention and cure for hypertension in China is faced with very tough challenges. Less than 40% of hypertension patients are aware of their illness, while only one-fourth of them are under proper management. Among those who are under management, 60% are willing to take medicines, while only 50% of them have their blood pressure under control. According to CRI, more than CNY 40 billion is annually spent on hypertension treatment in China. In 2013, market size of antihypertensive prescription drug in China exceeded CNY 20 billion, increased more than 15% YOY. This has shown great potential of Chinese market. The CAGR of sales value of telmisartan surpassed 65% in Chinese sample hospitals from 2005 to 2010. Its growth rate dropped slightly in 2011, but an annual growth rate of 10% is still maintained. From the perspective of sales revenue, original drug produced by Boehringer Ingelheim has seized most of Chinese telmisartan market while other market share is occupied by generic drugs produced by manufacturers such as Yichang Changjiang Pharmaceutical Co., Ltd. and Beijing Double-Crane Pharmaceutical Co., Ltd. It is estimated that incidence of hypertension in China will continue to rise year by year due to improvement of living standard, changes of eating habit, increasing stress of life and lack of health awareness. As Chinese people's incomes increase, the affordability of antihypertension drugs increases. Estimation shows that market size of telmisartan in China will keep rising in the next few years. For more information visit http://www.researchandmarkets.com/research/jq...estigation
China Adalimumab Market Investigation Report with 2018 Forecasts Now Available at ChinaMarketResearchReports.com
PRWeb - Fri Mar 21, 9:31PM CDT
Adalimumab is a TNF (tumor necrosis factor) inhibiting antiinflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF Pharma by Abbott. In 2000 Abbott Laboratories took over Knoll with USD 6.9 billion. At the end of 2002 adalimumab was approved to the market by FDA.
After Yesterday's Decline of 1.44%, Abbott Laboratories Offers Investors Better Value
Comtex SmarTrend(R) - Thu Mar 20, 3:54PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $38.78 to a high of $39.64. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $39.04 on volume of 10.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Sucampo's NDA Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:05PM CDT
Sucampo Pharma recently announced that its New Drug Application (NDA) for the liquid formulation of Amitiza will not be filed in the second half of 2014.
Drug Device Combination Products Market Report 2013 - 2019: Forecasts & Trends for the $US100 Billion Market
M2 - Tue Mar 18, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wmt3kk/drug_device) has announced the addition of the "Drug Device Combination Products Market Report 2013 - 2019: Forecasts & Trends for the $US100 Billion Market" report to their offering. The global drug device combination products market was valued at USD 66 billion in 2012 and is expected to grow at a CAGR of 7.9% from 2013 to 2019, to reach an estimated value of USD 115 billion in 2019. This report studies the global market for drug device combination products from the perspective of product types. The market is thus segmented into drug eluting stents, infusion pumps, bone graft implants, photodynamic therapy, wound care combination devices, inhalers, transdermal patches and others including intraocular implants and drug eluting beads. The market for all these product segments is also analyzed for four major geographic regions namely North America, Europe, Asia and the rest of the world (RoW) regions. The markets for all these segments is analyzed and estimated in USD billion. Each of the segments have been analyzed on the basis of its current and future market size for the period 2011 to 2019, in terms of revenue generation in USD billion, considering 2011 and 2012 as the base years. The compounded annual growth rate (%CAGR) for each market segment has been provided for the forecast period 2013 to 2019 along with the estimations of market size. A competitive landscape, mapping all the market players and their respective market shares for 2012 are provided in this report for drug eluting stents and infusion pumps. A chapter on recommendations for existing and new entrants is also provided in this report. Drug Device Combination Products Market: - Drug Eluting Stents - Infusion Pumps - Photosensitizers - Orthopedic Combination Products - Wound Care Combination Products - Inhalers - Transdermal Patches - Intraocular Implants and Drug Eluting Beads Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Drug Device Combination Products, by Type, Size and Forecast, 2011-2019 (USD Billion) Chapter 5 Global Drug Device Combination Products, by Geography, 2011 - 2019 (USD Million) Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles - Abbott Laboratories - Alcon, Inc. - Allergan, Inc. - Arrow International, Inc. - Bausch & Lomb, Inc. - Boston Scientific Corporation - C.R. Bard, Inc. - CareFusion Corporation - Covidien PLC - Ethicon, Inc. - Medline Industries, Inc. - Medtronic, Inc. - Mylan, Inc. - Pinnacle Biologics, Inc. - Stryker Corporation - Terumo Corporation - W. L. Gore & Associates, Inc. For more information visit http://www.researchandmarkets.com/research/wm...rug_device
Next Resistance Level for Abbott Laboratories (ABT) is $39.88
Comtex SmarTrend(R) - Tue Mar 18, 10:44AM CDT
Abbott Laboratories (NYSE:ABT) has opened bullishly above the pivot of $39.37 today and has reached the first level of resistance at $39.69. Investors may be interested in a cross of the next upside pivot targets of $39.88 and $40.39.
Global Imaging Biomarkers Market 2014-2018 with Abbott, Agilent, Affymetrix, Siemens, Bio-Rad & F. Hoffmann La Roche Dominating
M2 - Tue Mar 18, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brn9sx/global_imaging) has announced the addition of the "Global Imaging Biomarkers Market 2014-2018 with Abbott, Agilent, Affymetrix, Siemens, Bio-Rad & F. Hoffmann La Roche Dominating" report to their offering. The use of imaging biomarkers in the field of drug discovery has increased considerably over the past few years. The increase in the demand for imaging biomarkers is primarily because of their ability to be used in target discovery and validation, identification of disease mechanisms, toxicity profiling, and proof-of-concept studies. The Global Imaging Biomarkers market has been witnessing an increase in the number of strategic alliances being formed among organizations. Mergers and acquisitions help organizations grow rapidly, expand their business processes, and gain more market share. The introduction of innovative technologies by small and mid-sized companies is prompting major pharmaceutical and biotechnology companies to form strategic alliances with these smaller companies to identify various imaging biomarkers. The increase in strategic alliances is resulting in an increase in the application base for imaging biomarkers in drug discovery and diagnosis domains. For instance, in 2012, Genomic Health Inc. and OncoMed Pharmaceuticals announced a strategic alliance for Biomarker Research and Discovery using the Next-generation Sequencing process. Further, the report states that one of the main challenges hindering the growth of this market is the presence of poor regulatory and reimbursements systems. The current regulatory and reimbursement systems present in various countries are not well-suited for imaging biomarker-based diagnostics. The development of novel and useful imaging biomarkers is also an expensive and time-consuming process. The key vendors dominating this market space are: - Abbott Laboratories - Agilent Technologies Inc. - Affymetrix Inc. - Bio-Rad Laboratories Inc. - F. Hoffmann La Roche Ltd. - Gen-Probe Inc. - Siemens Healthcare. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Geographical Segmentation 08. Buying Criteria 09. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Trends and their Impact 15. Vendor Landscape 16. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/br...al_imaging
Critical Alerts For Yelp, SolarCity, MannKind, CVS, and Abbott Labs Released By InvestorsObserver
PR Newswire - Tue Mar 18, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for YELP, SCTY, MNKD, CVS, and ABT.
Eternity Healthcare to Initiate a Large Scale Clinical Trial of Its Needle-Free Injection System in Patients Undergoing Fertility Treatments Using the Drug Gonadotropins
Business Wire - Mon Mar 17, 7:25AM CDT
Eternity Healthcare Inc. (OTCBB: ETAH), a medical device and diagnostic company, announced today that they have signed an agreement with a major fertility clinic, Pacific Center for Reproductive Medicine. Eternity Healthcare and Pacific Center for Reproductive Medicine (PCRM) will partner for a large clinical trial that will use the Comfort-in(TM) Needle-Free Injection System in PCRM patients undergoing fertility treatments using the drug Gonadotropins.
Microfluidics Market Report 2013-2018: Materials, Pharmaceuticals, Drug Delivery Devices & IVD
M2 - Fri Mar 14, 9:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zswzc/microfluidics Normal 0 false false false EN-IE X-NONE X-NONE ) has announced the addition of the "Microfluidics Market Report 2013-2018: Materials, Pharmaceuticals, Drug Delivery Devices & IVD" report to their offering. The microfluidics market is segmented based on materials, products, and applications. This report studies market trends for the above mentioned segments in three industries, namely, pharmaceutical, in-vitro diagnostics, and drug delivery devices. The market is expected to grow at a strong CAGR during the study period. This is due to factors such as the rising demand for POC devices, quick return on investments provided by microfluidics devices which helps in cost reductions, and miniaturization of microfluidic chips. However, factors such as difficulty in incorporation of emerging microfluidic technologies into existing workflows and complex and time consuming regulatory standards are hampering the growth of this market. Microfluidics is defined as the science of designing, fabricating, and formulating products and processes that deal with low volumes of fluids in the range of nanoliters or picoliters. The technology evolved from MEMS (Micro Electro Mechanical Systems) devices and can replicate all the functions of its counterparts in various healthcare applications such as, drug delivery, Point-of-Care (POC), and clinical diagnostics. This study covers the materials, industries, and applications revenue markets for the global market. The global revenue generated from various microfluidics products used in three industries, namely, pharmaceutical, in-vitro diagnostics, and drug delivery devices is considered to estimate the market size. Material - Polymer-based Microfluidics - Glass-based Microfluidics - Silicon-based Microfluidics - Other Material-based Microfluidics Industry Pharmaceuticals - -- Microfluidic Chips for Laboratory Analytics - --- Toxicity Screening - --- Proteomics Analysis - --- Gene Sequencing - --- Capillary Electrophoresis - -- Accurate Dispensing Devices - -- Microreactors for Drug Synthesis - -- In-Vitro Diagnostics - --- Clinical Diagnostics - --- Point--- of--- Care Testing - --- Environmental Testing - --- Industrial Testing - --- Agro Food Testing - -- Drug Delivery Devices - --- Inhaler Nozzles - --- Micro Needles - --- Micro Pumps Application - Drug Delivery - Industrial and Environmental - Analytical Devices - Pharmaceutical and Life Sciences Research - Point-of-Care Diagnostics - Clinical and Veterinary Diagnostics Companies Mentioned - Abbott Laboratories, Inc. - Agilent Technologies - Bartels Mikrotechnik Gmbh - Becton, Dickinson And Company 1 Becton Drive - Bio-Rad Laboratories, Inc. - Biofluidix Gmbh - Cepheid, Inc. - Danaher Corporation - Fluidigm Corporation - Johnson & Johnson - Life Technologies Corporation - Microfluidic Chipshop Gmbh - Perkinelmer, Inc. - Raindance Technologies - Roche Diagnostics Limited - Scienion Ag - Siemens Healthcare For more information visit http://www.researchandmarkets.com/research/7z...rofluidics Normal 0 false false false EN-IE X-NONE X-NONE
Concise Analysis of the International Enteral Feeding Devices Market - Forecasts to 2016
M2 - Fri Mar 14, 5:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7v8b8b/global_enteral) has announced the addition of the "Concise Analysis of the International Enteral Feeding Devices Market - Forecasts to 2016" report to their offering. Currently, the increasing use of low-profile feeding tubes is replacing standard G-tubes used for providing enteral nutrition. Low-profile tubes provide feeds to patients directly through the abdomen. They terminate at skin level, are more easily hidden, and incur fewer accidental removals than G-tubes which have longer length of exposed tubing. Moreover, low-profile tubes with balloon can be replaced at home without the need for anesthetic or hospital admission. One of the main drivers in this market is the increase in rate of premature births. Preterm infants are not able to control and coordinate sucking, swallowing or breathing thus, generating the need for enteral feeding devices to provide them with sufficient nutritional requirements for growth and development. Further, the report states that one of the major challenges in the market is the complications with enteral feeding tubes such as tube blockage, aspiration pneumonia, and contamination of feed. The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are Nestl? HealthCare Nutrition Inc., Amsino International Inc., Applied Medical Technology Inc., Caesarea Medical Electronics, CORPAK MedSystems Inc., and Vygon Corp. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Vendor Landscape 9. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Key Vendor Analysis 16. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Amsino International Inc. - Applied Medical Technology Inc. - Caesarea Medical Electronics - CORPAK MedSystems Inc. - Covidienplc - Fresenius Kabi AG - Moog Inc. - Nestl? HealthCare Nutrition Inc. - Vygon Corp. For more information visit http://www.researchandmarkets.com/research/7v...al_enteral
SmarTrend Watching for Potential Rebound in Shares of Abbott Laboratories After 1.08% Loss
Comtex SmarTrend(R) - Thu Mar 13, 5:24PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $39.10 to a high of $39.82. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $39.41 on volume of 7.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Pre-Market Health Care Stocks Analysis: Medtronic, Abbott Laboratories, Hologic, and ArthroCare
PR Newswire - Thu Mar 13, 7:00AM CDT
On Wednesday, March 12, 2014, the NASDAQ Composite ended at 4,323.33, up 0.37%, the Dow Jones Industrial Average fell 0.07% to 16,340.08, and the S&P 500 closed at 1,868.20, up 0.03%. The gains were narrow based as four out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 687.90, down 0.01%, while the same has gained 3.36% in the last one month. Investor-Edge.com has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Hologic Inc. (NASDAQ: HOLX), and ArthroCare Corporation (NASDAQ: ARTC). Free research on these four companies can be accessed at:
2014 Hormone Replacement Therapy Global Strategic Business Report - IMS Consensus Guidelines Paving Way for More Clarity of HRT
M2 - Thu Mar 13, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/657h9p/hormone) has announced the addition of the "Hormone Replacement Therapy (HRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Hormone Replacement Therapy (HRT) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS & ISSUES 4. COMPETITIVE LANDSCAPE 5. THERAPY PROFILE - A REVIEW OF SELECT RECENT STUDIES CONDUCTED - Researchers at Yale University Discover Discontinuation HRT May Lead to Premature Deaths - Bioidenticals versus Synthetic Hormone Replacement Therapy Agents - Studies at University of Sydney Researchers Reveal the Safety of Short-Term Unopposed Estrogens - US Researchers Reveal HRT Risks May be Dependent on Weight and Other Factors - Studies Prove HRT to Lower Risk of Pancreatic Cancer - University of Texas Reveal HRT Linked to Risks of Kidney Stones - Researchers at the Sundsvall Hospital Demonstrate Increased Incidence of Cataract Development in Women Undergoing HRT - Researchers at University of Southern California Demonstrate Estrogen Replacement Therapies Lower Stress Levels in Older Women - Studies at Uppsala University Hospital Demonstrate HRT is Associated with Improved Muscle Functioning in Postmenopausal women - Finnish Study Reveals HRT Usage Assist in the Treatment of Hot Flashes in Post Menopausal Women - Researchers at Johns Hopkins University Demonstrate Women Undergoing Hormone Therapy Less Prone to Alzheimer's Disease - French Study Reveals Hormone Replacement Pills May Affect Gall Bladder - Danish Studies Proves HRT Lowers Risk of Heart Attack and Heart Failure 6. PRODUCT OVERVIEW 7. PRODUCT INTRODUCTIONS/APPROVALS - Pfizer Receives FDA Approval for DUAVEE for Treatment of Vasomotor Symptoms - Noven Pharmaceuticals Launches Brisdelle Capsules - Lawley Pharmaceuticals Launches Profeme progesterone Bioidentical Hormone Replacement Cream - Bayer Receives FDA Approval for Low-Dose ANGELIQ? Tablets - Noven Pharmaceuticals Receives USFDA Approval for Minivelle - Mylan Pharmaceuticals Introduces Letrozole Tablets - Novo Nordisk Unveils Vagifem? 10?g - Amgen Obtains FDA Approval for Prolia in Treating Postmenopausal Women at Greater Risk of Osteoporosis 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 40 companies including many key and niche players such as: - Abbott Laboratories - AbbVie - Actavis - Bayer Pharma - Bayer Pharma's Hormone Replacement Therapy Product Pipeline - Hisamitsu Pharmaceutical - Noven Pharmaceuticals - Merck Sharp & Dohme - Novartis - Novo Nordisk - Orion - Pfizer - Rottapharm Madaus - Teva Pharmaceutical Industries - TherapeuticsMD - Upsher-Smith Laboratories For more information visit http://www.researchandmarkets.com/research/657h9p/hormone About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Chinese Adalimumab Market Report - Forecasts to 2018
M2 - Wed Mar 12, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/936hbj/investigation) has announced the addition of the "Chinese Adalimumab Market Report - Forecasts to 2018" report to their offering. Adalimumab is a TNF (tumor necrosis factor) inhibiting anti-inflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF Pharma by Abbott. In 2000 Abbott Laboratories took over Knoll with USD 6.9 billion. At the end of 2002 adalimumab was approved to the market by FDA. Duo to large market size, challenging R&D and high profit of the monoclonal antibody drug market, the collaboration between Huahai Pharmaceutical and Oncobiologics is praised by the industry as the ""Second Transformation"" supported by the international biopharmaceutical giant's strong R&D strength. The approval for adalimumab to launch phase I clinical trial means a significant progress of the collaboration. However, follow-up R&D of the monoclonal antibody product requires a large amount of time before the product appears on the market. It is estimated that Abbott will continue to occupy the global market of adalimumab in the next few years. However, the situation will change gradually after 2017. Key Topics Covered: 1 Relevant Concepts of Adalimumab 2 Market Overview of Adalimumab in China, 2010-2013 3 Investigation on Sales Value of Adalimumab in China, 2010-2013 4 Investigation on Market Share of Major Adalimumab Manufacturers in China, 2010-2013 5 Investigation on Market Size of Adalimumab by Dosage Form in China, 2010-2013 6 Reference Price of Adalimumab in China Adalimumab Hospital Market, 2013 7 Analysis on Major Adalimumab Manufacturers in China, 2010-2013 8 Prospect of China Adalimumab Market, 2014-2018 Companies Mentioned - AbbVie - BASF Bioresearch Corporation - BASF Pharma - Huahai Pharmaceutical For more information visit http://www.researchandmarkets.com/research/93...estigation
Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Wed Mar 12, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mdgmns/rapid_medical) has announced the addition of the "Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid medical diagnostic kits market is experiencing impressive growth globally because of the continuous increase in demand for preventive management of infectious diseases. Since its introduction, rapid medical diagnostic kits are becoming a vital part of the medical diagnostics industry and the scope of this market has been perpetually increasing in terms of detectable diseases and adoption by end users. This report studies the global market for rapid diagnostic kits through three major perspectives namely, application areas, technologies and geography. The application segment of this market has been further segmented into three sub-divisions namely clinical testing, home-use and veterinary diagnostics. In addition, the technology segment of rapid medical diagnostic kits market has been categorized into lateral flow, flow-through, agglutination assays and solid phase. Each of the above segments are analyzed on the basis of their market size (in terms of USD million) for the period 2011 to 2019. This also includes the forecast of the market segments in terms of CAGR (%) for the period 2013 - 2019, considering 2012 as the base year. Geographically, the rapid medical diagnostic kits market is categorized into four regions namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market revenues (for the period 2011 - 2019) and forecast (for the period 2013 - 2019) for each of these regions have been included in this report. The market overview section of the report demonstrates the qualitative analysis of the market dynamics of the global rapid medical diagnostic kits market and thus includes information about the drivers, restraints, opportunities, Porter's five forces model and market attractiveness analysis of this industry. Key Topics Covered: Introduction Executive Summary Rapid Medical Diagnostic Kits Market Overview Global Rapid Medical Diagnostic Kits Market, by Applications, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Technology, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Geography, 2011 - 2019, (USD Million) Recommendations Competitive Landscape Companies Mentioned - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - MegaCor Diagnostik GmbH - F. Hoffmann-La Roche Ltd. - Trinity Biotech plc - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/md...id_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The US Nutraceuticals Market is Estimated to Reach US$ 75.3 Billion in 2017 says recent Report
M2 - Tue Mar 11, 11:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78hlpr/us_nutraceuticals) has announced the addition of the "US Nutraceuticals Market Forecast to 2017" report to their offering. In the latest research study, US Nutraceuticals Market Forecast to 2017, RNCOS analysts identified and deciphered the market dynamics in important segments to clearly highlight the areas offering promising possibilities for companies to boost their growth. The market, which is estimated to reach US$ 75.3 Billion in 2017, is slated to grow at a CAGR of nearly 6% during 2013-2017. The tremendous growth of the market is driven by factors such as rising consumption of dietary supplements and propelling functional food & beverages market. In the present report, the US nutraceutical market has been broken down into three distinct segments: dietary supplements, functional food and functional beverages, with their current and future outlook to 2017. For market performance analysis, the dietary supplements dominate the market by acquiring a share of around 37%, followed by functional food and functional beverages. In addition, the report also covers the nutraceutical ingredient market along with its sub segments which helped the analysts to clearly identify and highlight the segments that offer the maximum opportunity for growth in the country. The study further delves into the detailed description of the major players in industry, covering description of their business, financials, and their recent developments. This will help the reader to gain a deeper insight into each key market player. Moreover, market drivers and trends have been discussed along with consumer behavior analysis and regulatory framework analysis to provide an understanding of the market dynamics. Companies Mentioned: - Abbott Laboratories - GNC Holdings, Inc. - Mead Johnson Nutrition Company - NBTY Inc. - Nestle USA, Inc. - Perrigo Company - The Hain Celestial Group, Inc. For more information visit http://www.researchandmarkets.com/research/78...aceuticals About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Abbott Laboratories (ABT) Breaks Through Resistance at $40.00
Comtex SmarTrend(R) - Tue Mar 11, 9:31AM CDT
Abbott Laboratories (NYSE:ABT) has opened bullishly above the pivot of $39.71 today and has reached the first level of resistance at $40.00. Should the shares continue to rise, the resistance pivots of $40.19 and $40.67 will be of interest.
Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017
M2 - Tue Mar 11, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nc4zfn/in_vitro) has announced the addition of the "Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017" report to their offering. The in vitro diagnostic market studied in this report has been segmented by technology, product type, application, end user, and geography. The technology market is further segmented into clinical chemistry, immunochemistry, molecular diagnostics, hematology, coagulation, microbiology, and others, of which immunochemistry accounted for the largest share with 25.8% in 2010. By product type, the IVD market has segments like instruments, reagents, data management software/hardware, and services. Based on applications, the in vitro diagnostic market is segmented as diabetes, infectious diseases, oncology, cardiology, nephrology, auto-immune diseases, AIDS, drug testing, and others. Laboratory testing, hospital testing, academic (AMCs and university) testing, point-of-care testing, patient self-testing, and others comprise the end-user segment of the IVD market. The global in vitro diagnostic market was valued at $49.2 billion in 2012 and is expected to reach $69.1 billion by 2017, at a CAGR of 7% from 2012 to 2017. The IVD market is primarily driven by rising incidences of chronic and infectious diseases in emerging economies, a rapidly aging population, the rise in point-of-care testing, and the rising importance of personalized medicine. However, factors such as stringent regulatory frameworks and a shortage of budget and labor are restraining the growth of the market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global In Vitro Diagnostic Market, By Technique 5 Global In Vitro Diagnostic Market, By Product Type 6 Global In Vitro Diagnostic Market, By Application 7 Global In Vitro Diagnostic Market, By End-User 8 Geographic Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc - Alere, Inc - Arkray, Inc - Bayer AG - Becton, Dickinson And Company - Bio-Rad Laboratories, Inc - Biomerieux - Danaher Corporation - Diagnostica Stago Sas - Diasorin SPA - Hologic, Inc - Horiba, Ltd - Johnson & Johnson - Novartis International Ag - Qiagen NV - Roche Diagnostics Limited - Siemens Healthcare - Sysmex Corporation - Thermo Fisher Scientific, Inc For more information visit http://www.researchandmarkets.com/research/nc4zfn/in_vitro
2014 Wireless Health and Fitness Devices Global Strategic Business Report - Increasing Obesity Levels Underpins Market Growth
M2 - Tue Mar 11, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/swfb49/wireless_health) has announced the addition of the "Wireless Health and Fitness Devices - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Wireless Health and Fitness Devices in Thousand Units by the following Product Segments: Wireless Sports & Fitness Devices, Wireless Remote Health Monitoring Devices, and Wireless Professional Healthcare Devices. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2011 through 2020. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK - Wireless Health and Fitness Monitoring Devices Market to Surge - Market Drivers - Wearable Sports and Fitness Devices - Wearable Health Devices - Market Challenges - Wearable Sports and Fitness Devices - Wearable Health Devices 2. TRENDS & ISSUES 3. WIRELESS HEALTH AND FITNESS SOLUTIONS - AN OVERVIEW - Wireless Health and Fitness: An Introduction - Product Segments - Wireless Sports & Fitness Devices - Wireless Remote Health Monitoring Devices - Wireless Professional Healthcare Devices - What is Wireless Health? - Evolution of Wireless Health - Wireless Health Development with M2M Solutions - Value Chain in Mobile Healthcare - Available Wireless Medical Solutions - Wireless Standards for Medical Applications - ZigBee - Bluetooth - Broadband - Wireless Sensor Networks - Applications of Wireless Sensors for Enhanced Healthcare - Chronic Disease Monitoring - Personal Wellness Monitoring - Personal Fitness Monitoring - Benefits of Using Wireless Healthcare Solutions - More Affordable Healthcare - Preventive Healthcare - Better Accessibility to Healthcare - Chronic Disease Management - Key Benefits of Wireless Remote Patient Monitoring Devices - Primary Factors Limiting Success of Remote Patient Monitoring Devices 4. PRODUCT/SERVICE INNOVATIONS/ INTRODUCTIONS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. JAPAN 3. EUROPE 4. ASIA-PACIFIC 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 136 companies including many key and niche players such as: - Abbott Laboratories - Adidas - Alive Technologies - Beuer - BodyMedia - Bosch Healthcare - Entra Health Systems - FitLinxx - Fitbit - Garmin - Ideal Life - Intelesens - Isansys Lifecare - Jawbone - Lumo BodyTech - Medtronic - Nike - Nonin Medical, - Nuvon - Oregon Scientific - Philips Healthcare - Polar Electro - Sensei - Sotera Wireless - Suunto - Toumaz UK - Wahoo Fitness - Withings - Zephyr Technology For more information visit http://www.researchandmarkets.com/research/sw...ess_health About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Investigation Report on China's Telmisartan Market Report 2014 - Forecasts to 2018
M2 - Mon Mar 10, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jqmhqf/investigation) has announced the addition of the "Investigation Report on China Telmisartan Market, 2009-2018" report to their offering. According to statistics from WHO, one-third of the world's adults have high blood pressure. Death toll of this disease equals to half of the total number caused by stroke and heart attack. Angiotensin II receptor antagonist (ABR) is an important product among various antihypertensive drugs. Telmisartan was firstly developed by Boehringer Ingelheim and approved to the U.S. market for the first time in 1999 with the trade name ""Micardis"". It is a once-daily oral medication for the treatment of essential hypertension. In the same year, telmisartan was jointly sold as ""Micardis"" by Boehringer Ingelheim and ""Pritor"" by Glaxo Wellcome in Germany. It was approved to market in December 1999 in Philippines. In 2000, it was approved to market in Australia, Belgium and Britain. Glaxo Wellcome owns the marketing right worldwide except in Japan and the U.S. The company is also developing compound preparation of telmisartan and other hypertension drugs. Abbott Laboratories holds the sales license of this product in the United States. At the end of 2000, Boehringer Ingelheim introduced raw material and preparation of telmisartan into Chinese market. Several telmisartan generic drugs have also been approved to Chinese market in succession since 2004. Statistics shows that incidence of hypertension among Chinese people aged 15 and above is 24%. There are more than 260 million hypertension patients in the country, with at least one hypertension patient among 5 adults. The prevention and cure for hypertension in China is faced with very tough challenges. Less than 40% of hypertension patients are aware of their illness, while only one-fourth of them are under proper management. Among those who are under management, 60% are willing to take medicines, while only 50% of them have their blood pressure under control. According to CRI, more than CNY 40 billion is annually spent on hypertension treatment in China. In 2013, market size of antihypertensive prescription drug in China exceeded CNY 20 billion, increased more than 15% YOY. This has shown great potential of Chinese market. The CAGR of sales value of telmisartan surpassed 65% in Chinese sample hospitals from 2005 to 2010. Its growth rate dropped slightly in 2011, but an annual growth rate of 10% is still maintained. From the perspective of sales revenue, original drug produced by Boehringer Ingelheim has seized most of Chinese telmisartan market while other market share is occupied by generic drugs produced by manufacturers such as Yichang Changjiang Pharmaceutical Co., Ltd. and Beijing Double-Crane Pharmaceutical Co., Ltd. It is estimated that incidence of hypertension in China will continue to rise year by year due to improvement of living standard, changes of eating habit, increasing stress of life and lack of health awareness. As Chinese people's incomes increase, the affordability of antihypertension drugs increases. Estimation shows that market size of telmisartan in China will keep rising in the next few years. For more information visit http://www.researchandmarkets.com/research/jq...estigation
